Articles Tagged With:
-
Trump HHS Eases Standards Regarding Opioid Addiction Care; Biden Admin Reverses Course
More physicians would have been able to prescribe buprenorphine and other medication-assisted treatment for opioid use disorder, but the incoming administration reversed course.
-
Streamlined Lyme Disease Guidelines for Frontline Providers
With the peak period for Lyme disease approaching, new guidelines help clinicians understand when to consider the ailment in patients who present to the ED, how to properly diagnosis a case, and how to treat.
-
Tools Keep Tabs on Patients Remotely, Predicting Outcomes and Conserving Resources
Researchers developed an automated text messaging approach that can monitor patients who have been discharged from the ED. Other investigators have leveraged artificial intelligence to train an algorithm to help emergency clinicians better predict outcomes and manage resources.
-
Leaders Plot How They Will Leverage the Lessons of COVID-19
Caregiver well-being, peer support, and accelerated technology should factor into what happens next after the pandemic.
-
COVID-19 Exposed America’s Healthcare Faultlines. What Now?
Healthcare leaders and policymakers are working to correct these problems. They are reaching out to underserved communities to better understand their needs and concerns.
-
Biden Administration Takes First Steps Against COVID-19
The new president signed a series of executive actions to accelerate nation’s pandemic response.
-
FWA Revisited: ‘Checking the Box’ and IO Responsibilities Under the Revised Common Rule
Revisions to the Common Rule took effect in 2018, but questions remain about how these changes have affected the Federalwide Assurance (FWA) and institutional responsibilities under the FWA.
-
Chief Ethical Considerations for Continued COVID-19 Vaccine Research
The COVID-19 pandemic has created more uncertainty in human research protections in 2021. One issue IRBs will face is whether the benefits continue to outweigh the risks for people who enroll in COVID-19 vaccine studies.
-
Research World Can Help Build Trust Among Minorities
The COVID-19 vaccine rollout has raised issues about trust among many Americans who are hesitant or unwilling to take the vaccine. The issue of trust is especially problematic among minority communities that have been harmed in historic medical and research incidences. People also are skeptical of a vaccine that was developed in record time, considering most vaccines take 10-15 years to make it to market.
-
Research Trust Issues Affect Vaccine Rollout
The first month of the COVID-19 vaccine rollout among frontline healthcare workers was a reality check to the human research world after many people said no to the vaccine. There are several reasons for vaccine hesitancy, including distrust in the accelerated vaccine development process.